300255.SZ
300255.SZ
CNE1000016C2
CHANGSHAN PHARMA
Loading chart...

Company Profile

Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services. It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.

Related stocks

9969.HK
9969.HK • China
INNOCARE
12.73 HKD
2.87B USD 1Y -23.4%
002007.SZ
002007.SZ • China
HUALAN BIO.
13.35 CNY
3.65B USD 1Y -17.6%
600161.SS
600161.SS • China
BEIJING TIANTAN BIOLOGICAL PROD
12.73 CNY
3.77B USD 1Y -34%
9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
300009.SZ
300009.SZ • China
ANKEBIO
8.53 CNY
2.13B USD 1Y -17.1%
2696.HK
2696.HK • China
HENLIUS
50.75 HKD
3.53B USD 1Y -33%
301080.SZ
301080.SZ • China
ACROBIOSYSTEMS
122.2 CNY
3.06B USD 1Y +98.2%
688166.SS
688166.SS • China
BRIGHTGENE BIO-MEDICAL TECHNOLO
33.53 CNY
2.19B USD 1Y -41.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
68.0% p.a.
Max Drawdown (5Y)
-68.6%
Sharpe Ratio (5Y)
0.33
Beta Factor
0.32
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 244%.
Unprofitable business model: The company is currently generating net losses.
Elevated Short-Term Volatility: 3Y volatility (77.8%) is noticeably higher than the 5Y average (68.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (68.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -68.6% in the extended horizon.
ende